A SET OF 3 URINARY BIOMARKERS AS A PROGNOSTIC/DIAGNOSTIC FOR KIDNEY DISEASE

This technology relates to the use of 3 biomarkers present in urine that can be used to predict kidney disease progression.

Briefly, Dr. Böttinger and colleagues have discovered a set of 3 biomarkers that can be used over time to determine the likelihood of disease progression in patients with kidney disease. The technology has been demonstrated in a cross-sectional cohort of 620 individuals where these biomarkers are elevated in those with lowest eGFR in multivariable models adjusted for age, sex, race, proteinuria and history of disease. The predictive power of the biomarkers increases with added data points. The earliest significant difference is observed in patients that have no less than three data points over a period of 18 months.

Currently, these biomarkers are being validated in a prospective longitudinal study of a cohort of the Chronic Renal Insufficiency Cohort (CRIC) Study. The CRIC Study represents the largest, nationally representative prospective cohort of adults with chronic kidney disease with intended long-term follow up.

Current Development Status

• Clinical validation of the urinary biomarkers as a diagnostic/prognostic in a prospective longitudinal study (CRIC Study)

Applications

• Diagnosis of individuals with kidney disease
• Prognosis of evolution of kidney disease (rapid-progressor vs non-progressors)

Advantages

• Lack of biomarkers for kidney disease progression

Publications

• Not available

Patent Status

• International Application PCT/US2014/064592 filed November 7, 2014
• Status: Published. International Publication No. WO 2015/070041

Contact

Alan Belicha, PhD
Business Development Analyst
Mount Sinai Innovation Partners | Icahn School of Medicine at Mount Sinai
Phone: 646.605.7306